Zura Bio (ZURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 May, 2026Board of directors and corporate governance
Someit Sidhu resigned from the board of directors effective May 21, 2026, with no disagreements regarding company operations, policies, or practices.
Voting matters and shareholder proposals
Definitive additional proxy materials were filed, indicating ongoing or upcoming shareholder voting matters.
Shareholder rights and capital structure
Class A Ordinary Shares are registered and traded on The Nasdaq Stock Market under the symbol ZURA.
The company is incorporated in the Cayman Islands and is classified as an emerging growth company.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zura Bio
- Advancing a first-in-class bispecific antibody for major immune diseases, with strong funding and pipeline.ZURA
Corporate presentation - Q2 net loss rose to $26.3M as R&D spending surged; cash runway extends through 2028.ZURAQ2 2026
- Lead assets in SSc and HS target 2026 readouts, with major external catalysts expected in 2025.ZURAPiper Sandler 36th Annual Healthcare Conference
- Tibulizumab targets dual immune pathways in HS and SSc, with pivotal Phase 2 data expected by 2027.ZURACorporate presentation
- Tibulizumab targets dual immune pathways in Phase 2 trials for HS and SSc, aiming for market leadership.ZURACorporate presentation
- Q1 net loss increased to $24.2M, but cash reserves rose to $225.6M after a $144M equity raise.ZURAQ1 2026
- Tibulizumab targets dual immune pathways in Phase 2 trials for HS and SSc, with data expected 2026–2027.ZURACorporate presentation
- Proxy covers director elections, auditor ratification, equity plan changes, and governance updates.ZURAProxy filing
- First-in-class dual-pathway antibody in Phase 2 for HS and SSc, targeting major unmet needs.ZURACorporate presentation